By Brad Sorensen, CFA
OTC:BSEM
READ THE FULL BSEM RESEARCH REPORT
BioStem Technologies, Inc. (OTC:BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company states its mission is “to discover, develop and produce the most effective regenerative medicine products in the world,” and we believe that the company is well on its way to achieving that goal—providing to investors what we believe is an opportunity to invest in a company that is both providing a vital service to the human population and providing economic value to shareholders when doing so.
The company continues to release positive news, both for investors and patients. Earlier this quarter, management preannounced preliminary results that showed record 4Q net revenues and we are looking forward to that being confirmed in the soon-to-be-released 2024 fiscal results. Additionally, the company continues the process of uplisting its stock to the NASDAQ stock exchange, which should improve access and liquidity for investors in BSEM.
The company also just announced that its proprietary amnion chorion allograft, known as BioRetain has been approved by the Institutional Review Board (IRB) for the treatment of venous leg ulcers. This follows the announcement of the publication of a peer-reviewed study showing breakthrough results regarding the application of this product for diabetic foot ulcers. BioStem continues to demonstrate that its products, including BioRetain, outperform existing products and are drawing increasing interest from doctors and patients, which is why we continue to have a very positive view on BSEM.
Summary
We reiterate our belief in the direction of BSEM and urge investors to take a look at the stock and consider adding it to a portfolio.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.